I think my expectations depend on the ADF label of Remoxy. If PTIE gets a label to deter all three main routes of abuse (oral, injection, snorting) - then the Remoxy value proposition is superior to most other approved ADFs and my expectation for the market potential is somewhere at $300+ million (15+% of ER opioid market). This way I expect and derive a fair company value for a buyout of 3 x $300+ million = $900+ million = $900 million / 46 million shares = $20+ per share.
I sold CTSO in order to shift the money to EDT.TO - because EDT.TO has an earlier key milestone concerning a final pivotal phase 3 bacterial induced sepsis trial. If my strategy works (and, yes, there is some risk that EDT.TO will fail to prove a survival benefit with it's device) - then I will again divest EDT.TO and invest the money in CTSO for the long run. I am a full believer in CTSO's technology - and the weekly case reports clearly demonstrate that CTSO's device will provide an outstanding survival benefit - but we need a controled pivotal study with an survival adavante endpoint in order to get a final US approval. Nevertheless the revenue at CTSO will continue to climb outside US ......